A High-Throughput Clinical Laboratory Methodology for the Therapeutic Monitoring of Ibrutinib and Dihydrodiol Ibrutinib

Ibrutinib (IBR) is an oral anticancer medication that inhibits Bruton tyrosine kinase irreversibly. Due to the high risk of adverse effects and its pharmacokinetic variability, the safe and effective use of IBR is expected to be facilitated by precision dosing. Delivering suitable clinical laborator...

Descripción completa

Detalles Bibliográficos
Autores principales: Karvaly, Gellért Balázs, Vincze, István, Balogh, Alexandra, Köllő, Zoltán, Bödör, Csaba, Vásárhelyi, Barna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331678/
https://www.ncbi.nlm.nih.gov/pubmed/35897942
http://dx.doi.org/10.3390/molecules27154766

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331678/
https://www.ncbi.nlm.nih.gov/pubmed/35897942
http://dx.doi.org/10.3390/molecules27154766

Ejemplares similares